Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, et al.
Antiviral Research (2022) Vol. 208, pp. 105430-105430
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

The evolution of SARS-CoV-2
Peter V. Markov, Mahan Ghafari, Martin Beer, et al.
Nature Reviews Microbiology (2023) Vol. 21, Iss. 6, pp. 361-379
Open Access | Times Cited: 724
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Med (2024) Vol. 5, Iss. 1, pp. 42-61.e23
Open Access | Times Cited: 17
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
Davide Marangoni, Roberta Maria Antonello, Marco Coppi, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 53-56
Open Access | Times Cited: 27
Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
Divya Teli, Pankti C. Balar, Kishan Patel, et al.
Metabolites (2023) Vol. 13, Iss. 2, pp. 309-309
Open Access | Times Cited: 25
Early combination therapy of COVID-19 in high-risk patients
Hans Martin Orth, Charlotte Flasshove, Moritz Berger, et al.
Infection (2023) Vol. 52, Iss. 3, pp. 877-889
Open Access | Times Cited: 21
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study
Ming Hong Choi, Eric Yuk Fai Wan, Ian Chi Kei Wong, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 11, pp. 1213-1224
Closed Access | Times Cited: 8
The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development
Zhen Zhang, Li Zhou, Qianyun Liu, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 34
Viral proteases as therapeutic targets
Taťána Majerová, Jan Konvalinka
Molecular Aspects of Medicine (2022) Vol. 88, pp. 101159-101159
Open Access | Times Cited: 31
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
JCI Insight (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 30
Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review
Piotr Rzymski, Maria Pokorska‐Śpiewak, Teresa Jackowska, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1502-1502
Open Access | Times Cited: 19
Antiviral combination therapies for persistent COVID-19 in immunocompromised patients
Daniele Focosi, Fabrizio Maggi, Alessandra D’Abramo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 55-59
Open Access | Times Cited: 17
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109049-109049
Open Access | Times Cited: 6
Structure-Based Optimization of Pyridone α-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease
A. Ravi Kumar, Haifa El Kilani, Alina Metzen, et al.
Journal of Medicinal Chemistry (2025)
Open Access
Intranasal liposomal remdesivir induces SARS-CoV-2 clearance in K18-hACE2 mice and ensures survival
Sabrina Mendes, Lays Cordeiro Guimarães, Leonardo Camilo de Oliveira, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 558-573
Closed Access
Drugs for COVID-19: An Update
Jessica Ceramella, Domenico Iacopetta, Maria Stefania Sinicropi, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8562-8562
Open Access | Times Cited: 23
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 13
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models
Hong‐Yi Zheng, Tian‐Zhang Song, Yong‐Tang Zheng
动物学研究 (2024) Vol. 45, Iss. 4, pp. 747-766
Open Access | Times Cited: 4
Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
Daisy Yan, Bingfang Yan
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 4, pp. 726-738
Open Access | Times Cited: 10
Aprotinin—Drug against Respiratory Diseases
Alexandre V. Ivachtchenko, Andrey A. Ivashchenko, Dmitrii O. Shkil, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11173-11173
Open Access | Times Cited: 10
N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
Arne Zibat, Xiaoxiao Zhang, Antje Dickmanns, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107786-107786
Open Access | Times Cited: 10
A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir
Yumin Zhang, Yuan Sun, Yuanchao Xie, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 10
Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant
Cosimo Cianfarini, Luise Hassler, Jan Wysocki, et al.
Cells (2024) Vol. 13, Iss. 3, pp. 203-203
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top